Latest articles and publications

This is a common question from my patients with wet (neovascular AMD). Here I present two studies discussing the injection burden over time.

You will need to do this well to improve clinic attendance, adherence to treatment, and have happy patients!

The US FDA approved the use of pegcetacoplan (Syfovre) and avacincaptad pego (Izervay) for the treatment of geographic atrophy (GA) in 2023. How can this help GA patients in New Zealand?

A patient came to see me wanting Vabysmo for his neovascular AMD. He is looking at delaying retirement and even selling down asset to fund for this treatment. How would I advise him?

A story on regaining independence against the odds

Cataracts, dementia and falls are all common, yet debilitating, health conditions of the elderly. Here I examine the evidence for cataract surgery and its link to reducing the risk of dementia and falls, and how improving access to this surgery is likely to benefit our New Zealand cataract patients.

The use of intravenous (IV) thrombolytic therapy, namely tissue plasminogen activator (tPA), is the current mainstay treatment for cerebral ischemic stroke. But what role could it play in CRAO? I review the evidence and provide some insights on how we can approach the treatment of CRAO in clinical practice.

A cautionary tale on Optos imaging.

My August 2023 Research Review article summarising the latest ophthalmic publications - approved for CME points by RANZCO, RNZCGP and The College of Nurses Aoteroa.

Are the newly FDA-approved Pegcetacoplan and Avacincaptad Pegol a game-changer for treating non-neovascular (dry) AMD? Here are my thoughts.

A patient with a blurred spot in his vision in the right eye. Examination shows a Weiss ring. Is the posterior vitreous detachment the cause of his symptoms?

Sometimes patients can present with vision loss, but despite a detailed assessment, no obvious cause is found. Here I demonstrated three useful techniques on the Spectralis viewing platform to help assess patients with vision loss of unclear cause.

You may come across Zaltrap, or ziv-aflibercept, in treating retinal disease. Exactly what is this, and when is it used in intravitreal injections? This post will answer your questions.

Most patients do not look forward to their intravitreal injections. Here I outline six techniques to ensure my intravitreal injections are as pain-free as possible.

A discussion of using artificial intelligence in geographic atrophy

This post will discuss the most recent literature surrounding OCT characterisation of geographic atrophy.

This post will summarise the recent trial of using Pegcetacoplan for the treatment of GA. Furthermore, we will look at the assessment of GA using different imaging modalities to help inform the risk of vision loss and to identify patients who maybe suitable for treatment when it becomes available.